Treace Medical Concepts

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Treace Medical Concepts (TMCI) reports stellar revenue growth and innovation plans

Treace Medical Concepts (TMCI) delivered exceptional revenue growth in 2022, exceeding expectations and showcasing strong market positioning. With a focus on innovation, specialized sales strategies, and complementary products, TMCI is poised for continued success. While challenges like sustaining growth exist, the company's strategic investments and upcoming product releases present promising opportunities for future expansion.

Treace Medical Concepts (TMCI) reports robust Q1 growth and raises full-year revenue guidance

Treace Medical Concepts (TMCI) delivered impressive Q1 2023 results, showcasing strong revenue growth and increased market penetration. With raised revenue guidance for the full year and a focus on strategic investments, TMCI is well-positioned for continued success and market expansion.

Treace Medical Concepts reports robust Q2 growth and strategic investments

Treace Medical Concepts (TMCI) delivered strong Q2 results with significant revenue growth, expanded market penetration, and strategic investments in growth initiatives.
While facing a net loss, the company improved adjusted EBITDA and raised full-year revenue guidance, supported by a robust financial position.
Challenges include managing expenses, pricing strategies, and surgeon satisfaction, but opportunities lie in upcoming product launches, reimbursement rates, and surgeon engagement.

Treace Medical Concepts reports strong Q3 revenue growth and outlines future growth strategies

Treace Medical Concepts delivered strong Q3 results with revenue up 23% YoY, despite challenges from soft surgery demand and delayed product launches.
The company's focus on innovation, market expansion, and operational efficiency positions it for future growth and improved financial performance.
While facing short-term challenges, Treace's strategic investments, strong cash position, and product pipeline offer opportunities for sustained growth and market leadership.
Overall, Treace's performance reflects resilience and adaptability in navigating market dynamics, with a clear focus on driving innovation and capturing market opportunities.

Treace Medical Concepts reports robust Q4 earnings and eyes market expansion

Treace Medical Concepts (TMCI) delivered strong financial results in Q4 2023, with revenue growth, positive adjusted EBITDA, and a positive outlook for 2024.
The company's focus on new technologies, market penetration, and efficient sales models positions it well for continued growth and market expansion.
While facing challenges in maintaining gross margins and optimizing sales team productivity, Treace remains optimistic about growth potential and strategic positioning.

Treace Medical Concepts reports robust Q1 growth amidst competitive challenges

Treace Medical Concepts demonstrates strong growth momentum and financial resilience in Q1 2024, driven by product innovation and strategic partnerships.
While facing challenges from increased competition and market pressures, the company remains agile with revised guidance and a focus on cost management.
Opportunities for expansion and differentiation through new product launches and market partnerships position Treace for continued success in the orthopedic medical device sector.

Treace Medical Concepts reports robust Q2 growth and eyes Medicare opportunities

Treace Medical Concepts (TMCI) delivered strong Q2 results and is poised for continued growth with a focus on innovation and market expansion.
While facing challenges in product launch and market competition, the company's commitment to R&D and leveraging regulatory changes provides a solid foundation for future success.
Opportunities in Medicare payment rate increases and new product introductions offer avenues for revenue growth and market leadership in the medical device industry.

Treace Medical Concepts reports Q3 growth, faces patent lawsuit

Treace Medical Concepts showed solid revenue growth in Q3 2024 despite facing a net loss. The company's Nanoplasty system and strategic focus on bunion cases present growth opportunities. Legal challenges and financial losses are key areas of concern.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Treace investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secu.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Treace Medical Concepts, Inc. (TMCI) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.

Treace Medical Concepts, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Treace Medical Concepts, Inc. (TMCI)

LOS ANGELES, CA / ACCESSWIRE / October 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholders To Help Investigate Whether Treace Medical Concepts, Inc. Violated Securities Laws

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI) investors concerning the Company's possible violations of federal securities laws. On May 7, 2024, Treace released its first quarter 2024 financial results and revised its full year 2024 guidance, lowering it by approximately $20 million, citing "increased use of MIS Osteotomy solutions and more competition from knockoffs.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Treace Medical Concepts, Inc. (TMCI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 7, 2024, Treace released its first quarter 2024 financial results and revised its full year 2024 guidance, lowering it by approximately $20 million, citing ".

The Law Offices of Frank R. Cruz Announces Investigation of Treace Medical Concepts, Inc. (TMCI) on Behalf of Investors

Levi & Korsinsky Announces an Investigation on Behalf of Treace Medical Concepts, Inc. (TMCI) Shareholders Who May Have Been Affected by Fraud

LOS ANGELES, CA / ACCESSWIRE / October 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm's Inquiry Into Treace Medical Concepts Inc For Securities Fraud

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.

Treace Medical Concepts, Inc. (TMCI) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

LOS ANGELES, CA / ACCESSWIRE / October 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.

Investors who lost money on Treace Medical Concepts, Inc. should contact Levi & Korsinsky about an ongoing investigation - TMCI

LOS ANGELES, CA / ACCESSWIRE / October 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Treace Medical Concepts Inc For Securities Fraud

TMCI ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Treace Medical Concepts, Inc. Shareholders Who Lost Money

LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholder Participation

LOS ANGELES, CA / ACCESSWIRE / October 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Treace Medical Concepts Inc For Securities Fraud

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.

Lost Money on Treace Medical Concepts, Inc. (TMCI)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

Treace to Report Third Quarter 2024 Financial Results on November 5, 2024

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Treace Medical Concepts, Inc. ("Treace Medical Concepts, Inc.") (NASDAQ:TMCI) concerning possible violations of federal securities laws. On May 7, 2024 Treace Medical Concepts Inc. announced Q1 2024 financial results that met revenue estimates but lowered its guidance for the full year 2024 blaming it on "competitive pressure in its business.

Treace Medical Concepts, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - TMCI

LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Encourages Shareholder Participation

PONTE VEDRA, Fla., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ®  and Adductoplasty ®  Procedures, today announced that it filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. (collectively, “Stryker”) (NYSE: SYK), alleging infringement of 9 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies and unfair competition. The suit was filed in the United States District Court for the District of New Jersey, and seeks injunctive relief and damages.

Treace Files Patent Infringement and Unfair Competition Suit to Protect Lapiplasty® Bunion Technology

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ®  and Adductoplasty ®  Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2024 in Vancouver, British Columbia, Canada from September 11-14, 2024.

Treace Highlights New Product Innovations and Updated Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024

PONTE VEDRA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ®  and Adductoplasty ®  Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, beginning at approximately 10:00 am ET.

Treace Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

Treace Medical Concepts Inc (TMCI) Q2 2024 Earnings Call Transcript

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.20 per share a year ago.

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

PONTE VEDRA, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the second quarter ended June 30, 2024.

Treace Medical Concepts Reports Second Quarter 2024 Financial Results

PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ®  and Adductoplasty ®  Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.

News for Treace Medical Concepts Stock (TMCI)